Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.

about

The Practical Consideration of Poliovirus as an Oncolytic Virotherapy

P2860

Q57012283-B11D1CD3-B6AD-41C1-8953-2E8910F5F04D

P2860

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.

Item

http://www.wikidata.org/entity/Q36106810

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Chemotherapy-induced neutropen ...... s with gynecologic malignancy.

@ast

Chemotherapy-induced neutropen ...... s with gynecologic malignancy.

@en

type

Item

label

Chemotherapy-induced neutropen ...... s with gynecologic malignancy.

@ast

Chemotherapy-induced neutropen ...... s with gynecologic malignancy.

@en

prefLabel

Chemotherapy-induced neutropen ...... s with gynecologic malignancy.

@ast

Chemotherapy-induced neutropen ...... s with gynecologic malignancy.

@en

P1476

Chemotherapy-induced neutropen ...... s with gynecologic malignancy.

@en

P2093

Mari Kasai

http://www.w3.org/2001/XMLSchema#string

Takeshi Fukuda

http://www.w3.org/2001/XMLSchema#string

Tomoyo Yasui

http://www.w3.org/2001/XMLSchema#string

Tomoyuki Ichimura

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Sumi

http://www.w3.org/2001/XMLSchema#string

Yasunori Hashiguchi

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings

Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.

Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours

Quality of life and chemotherapy-induced neutropenia.

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

P304

1054-1060

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CAD.0000000000000279

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26267078

http://www.w3.org/2001/XMLSchema#string

P932

4588600

http://www.w3.org/2001/XMLSchema#string

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.

about

P2860

P2860

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932